Therefore, studies that target IGFs/IGF-1R in multiple tumors with suitable molecular contexts, including IGF-1R suppression, are being conducted to efficiently treat triple-negative breast cancers rather than HR-positive metastatic breast cancers [128,129,130] as well as treat KRAS-mutant NSCLCs rather than wild-type lung cancers [58]. This evidence concerns the gene KRAS and triple-negative breast carcinoma.